Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00134602
Recruitment Status : Completed
First Posted : August 25, 2005
Last Update Posted : September 27, 2012
Jacobi Medical Center
Children's Research Institute
Howard University
Information provided by (Responsible Party):
Centers for Disease Control and Prevention

Brief Summary:

The purpose of the study is to develop and evaluate an intervention to promote adherence to HIV medications among children 5-12 years of age. It compares changes in antiretroviral (ARV) adherence between the EIG (enhanced intervention group) and an MIG (minimal intervention group) from baseline to 4 months post-intervention.

Secondary outcomes include examining whether improvement in adherence to a medication regimen is associated with improved health outcomes (i.e., viral load, CD4 counts, etc.); identifying and evaluating predictors and/or mediators of adherence; studying the feasibility of electronic recording in measuring adherence in an HIV-infected pediatric population; and evaluating the relationship between the amount of intervention received (i.e., number of hours/number of sessions) and changes in adherence.

Condition or disease Intervention/treatment Phase
HIV Infections Behavioral: Needs assessment followed by tailored intervention Not Applicable

Detailed Description:

The objective of this research is to develop and evaluate an intervention to promote adherence to HIV-medications among children aged 5-12 years. The research will be conducted at Jacobi Medical Center in the Bronx, NY; Children's National Medical Center in Washington, DC; and at Howard University Hospital in Washington, DC. The research will employ a randomized case control study design. Participants (dyads composed of an HIV-infected child and his/her primary caregiver) will be recruited from eligible families within each site's HIV clinic. After the study is explained and informed consent and assent (where applicable) are obtained, participants will be randomly assigned to either the enhanced intervention group (cases) or the minimal intervention group (controls). Participants assigned to the enhanced intervention group will receive a multi-component intervention, specifically tailored to their family's needs, which includes a maximum of 24 hours of contact conducted over a period of up to 12-weeks, and a 1-3 hour booster session approximately six weeks after the intervention phase is completed.

The enhanced intervention will be coordinated by an onsite Adherence Coordinator (AC) and implemented primarily by the AC or another member of the study staff. Participants assigned to the comparison group will receive a minimal intervention that will consist of an educational video and health education pamphlets about general health. All participants will continue to receive the standard-of-care at their respective sites during the study period. Assessments of all participants will be done at baseline (Assessment A), 1 month (Assessment B), and 4 months (Assessment C) following the intervention. Each assessment will include an interview to collect the following information from families:

  • socio-demographic data;
  • parental/child report of child's medication taking or adherence (self-reported adherence);
  • mental health functioning (of parents and child, using standardized measures);
  • HIV (of parents) and medication knowledge (of parents and child);
  • medical review of child's hospital chart.

The baseline assessment of adherence to medications will include electronic recording of medication taking via a MEMS® cap done over a four-week period. Ongoing electronic assessment of adherence will occur for the duration of the study. Pharmacy refill data will also be obtained for a portion of the study participants for whom data are available.

Study Type : Interventional  (Clinical Trial)
Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Intervention to Promote Adherence to Antiretroviral Medications Among HIV-infected Children 5-12 Years of Age
Study Start Date : April 2003
Actual Primary Completion Date : January 2007
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Improved adherence to antiretroviral treatment regimen

Secondary Outcome Measures :
  1. Improved viral load
  2. Improved CD4 count

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Families with a child between the ages of 5 and 12 years old who is HIV-infected and who receives care at participating hospitals
  • Informed consent for and assent from the child
  • Informed consent for the primary caregiver (person responsible for most of the child's medication delivery) must be obtained. The parent/legal guardian must be able to give informed consent and willing to comply with protocol requirements.
  • The HIV-infected child must be currently prescribed an antiretroviral therapy regimen.

Exclusion Criteria:

  • The child or caregiver cannot respond to self-report questions because of cognitive impairments.
  • The child receives home health care in which the home health care aide dispenses all of the child's medication (essentially resulting in directly observed therapy for that child).
  • The child and/or the caretaker does not speak English or Spanish.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00134602

United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
Howard University Hospital, Department of Pediatrics
Washington, District of Columbia, United States, 20060
United States, New York
Jacobi Medical Center
Bronx, New York, United States, 10461
Sponsors and Collaborators
Centers for Disease Control and Prevention
Jacobi Medical Center
Children's Research Institute
Howard University
Principal Investigator: Andrew Wiznia, MD Jacobi Medical Center, Bronx, NY
Principal Investigator: Tamara Rakusan, MD Children's Research Institute
Principal Investigator: Sohail Rana, MD Howard University Hospital, Pediatrics Department

Responsible Party: Centers for Disease Control and Prevention Identifier: NCT00134602     History of Changes
Other Study ID Numbers: CDC-NCHSTP-3660
First Posted: August 25, 2005    Key Record Dates
Last Update Posted: September 27, 2012
Last Verified: September 2012

Keywords provided by Centers for Disease Control and Prevention:
HIV infection, antiretroviral therapy, adherence, pediatric

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases